Xbrane Biopharma AB (FRA:7XB0) GF Value Rank: 3 (As of Aug. 27, 2026) — 50% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7XB0 Xbrane Biopharma AB FRA:7XB0
71 GF Score
Price €0.77
GF Value €0.49
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB GF Value Rank?

Xbrane Biopharma AB FRA:7XB0 -1.28% 71 GF Value Rank is 3 as of Aug. 27, 2026, which is 50% above its 10-year median of 2.00. GuruFocus rates FRA:7XB0 with a GF Score™ of 71/100 and a GF Value™ of €0.49. The stock has 6 warning signs investors should review.

Xbrane Biopharma AB has the GF Value Rank of 3.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Xbrane Biopharma AB GF Value Rank Related Terms

FRA:7XB0 vs VRTX, REGN, RVMD: GF Value Rank Comparison

For the Biotechnology subindustry, Xbrane Biopharma AB's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xbrane Biopharma AB GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's GF Value Rank falls into.


FRA:7XB0
71GF Score
Xbrane Biopharma AB FRA:7XB0
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 3 mean?
Xbrane Biopharma AB (FRA:7XB0) has a GF Value Rank of 3 as of Aug. 27, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Xbrane Biopharma AB and its competitors. This is 50% above median its historical median of 2.00. Over the past decade, Xbrane Biopharma AB's GF Value Rank has ranged from 1.00 to 10.00.
Is Xbrane Biopharma AB's GF Value Rank too high?
Xbrane Biopharma AB's current GF Value Rank of 3 is 50% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's GF Value Rank compare to VRTX and REGN?
Xbrane Biopharma AB's GF Value Rank of 3 can be compared against companies in the Biotechnology industry. Historically, Xbrane Biopharma AB's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current GF Value Rank is 3, which is 50% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Xbrane Biopharma AB (FRA:7XB0) has a current GF Value Rank of 3. The stock's GF Value™ is €0.49, compared to a current price of €0.77 — trading 57.6% above its estimated fair value. The current GF Value Rank is 3, which is 50% above median its 10-year median of 2.00. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Xbrane Biopharma AB (FRA:7XB0), the current GF Value Rank is 3 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (FRA:7XB0) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of €0.77 is trading 57.6% above its estimated GF Value™ of €0.49.

Key valuation signals for FRA:7XB0:

  • GF Value Rank: 3 (50% above median its 10-year median of 2.00)
  • GF Value™: €0.49 vs. price of €0.77 (57.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:7XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xbrane Biopharma AB Business Description

Other Exchanges XBRANE:Sweden
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score

Get the complete analysis for FRA:7XB0

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€0.49
GF Value